Rocket Pharmaceuticals CFO Aaron Ondrey Steps Down to Pursue New Opportunities
ByAinvest
Tuesday, Aug 26, 2025 1:13 am ET1min read
RCKT--
Ondrey joined Rocket Pharmaceuticals in March 2024 and served as the CFO until his resignation. His total compensation for 2024 was approximately $3 million [3]. Wilson, who joined the company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024, will take over the interim PFO role [3].
The resignation of Ondrey comes amidst significant developments for Rocket Pharmaceuticals. The company's pivotal Phase 2 trial of RP-A501 for Danon disease had a clinical hold lifted by the FDA in late July 2025 [2]. The FDA's decision to resume the trial, following a recalibrated dose and revised protocol, is a positive development for the company and its stock [2].
Rocket Pharmaceuticals' stock, RCKT, saw a 33.68% increase during the premarket session on Wednesday, August 25, 2025, following the FDA's decision [2]. The stock was trading at $3.91 at the time, indicating investor confidence in the company's progress.
The changes in Rocket Pharmaceuticals' leadership and the FDA's decision on the pivotal trial are significant developments for the company. Investors should closely monitor these developments for potential impacts on the company's financial performance and stock price.
References:
[1] https://www.tipranks.com/news/the-fly/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-to-pursue-other-opportunities-thefly
[2] https://www.benzinga.com/news/fda/25/08/47233429/fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy
[3] https://www.marketwatch.com/story/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-0a7dd960
Rocket Pharmaceuticals' CFO Aaron Ondrey resigned on August 20, 2025, to pursue other opportunities, with his last day being September 5, 2025. Martin Wilson, the company's General Counsel and Chief Corporate Officer, was appointed interim Principal Financial Officer on August 25, 2025, effective September 8, 2025.
Rocket Pharmaceuticals (RCKT) announced the resignation of its Chief Financial Officer (CFO), Aaron Ondrey, effective September 5, 2025. Ondrey will pursue other opportunities, as per a regulatory filing [1]. Martin Wilson, the company's General Counsel and Chief Corporate Officer, has been appointed as the interim Principal Financial Officer (PFO), effective September 8, 2025 [1].Ondrey joined Rocket Pharmaceuticals in March 2024 and served as the CFO until his resignation. His total compensation for 2024 was approximately $3 million [3]. Wilson, who joined the company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024, will take over the interim PFO role [3].
The resignation of Ondrey comes amidst significant developments for Rocket Pharmaceuticals. The company's pivotal Phase 2 trial of RP-A501 for Danon disease had a clinical hold lifted by the FDA in late July 2025 [2]. The FDA's decision to resume the trial, following a recalibrated dose and revised protocol, is a positive development for the company and its stock [2].
Rocket Pharmaceuticals' stock, RCKT, saw a 33.68% increase during the premarket session on Wednesday, August 25, 2025, following the FDA's decision [2]. The stock was trading at $3.91 at the time, indicating investor confidence in the company's progress.
The changes in Rocket Pharmaceuticals' leadership and the FDA's decision on the pivotal trial are significant developments for the company. Investors should closely monitor these developments for potential impacts on the company's financial performance and stock price.
References:
[1] https://www.tipranks.com/news/the-fly/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-to-pursue-other-opportunities-thefly
[2] https://www.benzinga.com/news/fda/25/08/47233429/fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy
[3] https://www.marketwatch.com/story/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-0a7dd960
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet